Alcohol Use Disorder

A number of Addex executives, including the CEO, will assume similar roles at Neurosterix. Image Credit: Red Vector / Shutterstock. Swiss company Neurosterix has launched into the neurological drug development scene with $63m in Series A funding to develop allosteric modulators for the treatment of neurological disorders. The company also purchased several preclinical assets for treating neurological disorders and the allosteric modulator drug discovery technology platform from Addex Therapeutics . Addex received SFr5m ($5.5m) and 20% equity in Neurosterix in exchange for the drug candidates and technology. The Series A financiers included US-based investment company Perceptive Advisors through the Perceptive Xontogeny Venture Fund II and Perceptive Life Sciences Fund, along with another US-based venture capital firm Acorn Bioventures. Neurosterix disclosed that its lead programme is a muscarinic acetylcholine receptor subtype 4 positive allosteric modulator (M4 PAM) for the treatment of schizophrenia. The company did not disclose the details of other preclinical pipeline assets. See Also: Intra-Cellular Therapies gets grant for amorphous solid dispersion of ITI-007 tosylate salt Obsidian raises $160.5m to advance TIL cell therapy programme The use of PAMs for the treatment of neurological disorders has been an area of focus in recent months. In December 2023, AbbVie agreed to acquire Cerevel Therapeutics for $8.7bn. Emraclidine, a selective M4 receptor PAM, was at the centre of the deal. Following the news of the asset purchase, Addex’s stock rose by more than 16.3% at the market close on 3 April, compared to the market close on the previous day. Addex’s CEO Tim Dyer will also serve as the CEO of Neurosterix, along with multiple executives who will assume dual roles at both Addex and Neurosterix. Addex added that it will retain the allosteric modulator assets that are being developed in partnerships with Johnson & Johnson (J&J) and Indivior , respectively. ADX71149 is a PAM of metabotropic glutamate receptor 2 (mGlu2 PAM), which is being developed in collaboration with J&J. It is being evaluated in a Phase IIa proof of concept clinical trial (NCT04836559) as a treatment for epilepsy. Data from the trial is expected in Q2 this year. Indivior has licensed the gamma-aminobutyric acid subtype B (GABA-B) PAM programme from Addex. INDV-1000, a GABA-B PAM, is in preclinical development as a treatment for alcohol use disorder . Furthermore, Addex also retains the rights to another drug, dipraglurant, and a GABA-B PAM candidate for the treatment of chronic cough. The company plans to start a Phase II trial evaluating dipraglurant, a metabotropic glutamate subtype 5 (mGlu5) negative allosteric modulator (NAM), for post-stroke sensorimotor recovery this year.

Twelve-acre Montgomery County campus adds custom built home for those seeking residential treatment for up to ninety days. ROCKVILLE, Md., April 3, 2024 /PRNewswire/ -- The Valley residential treatment center, a privately owned and operated treatment center is breaking ground on a new residential treatment home on a four acre plot of land at 10 Granby Court. Derwood, MD 20855. The new home, custom build and designed by The Valley will offer programs for patients with many levels of care including ninety day stays. Construction on the new center will begin in June. 10 Granby Court sits on an additional four acres of land connected to the eight acres currently home to The Valley treatment center. With the addition of the new Granby Court home, the campus will have a total of 48 beds. The Valley offers evidence-based inpatient treatment programs that integrates addiction treatment, substance use treatment, mental health treatment, and behavioral healthcare in a comprehensive, person-centered, therapeutic method. The new program will build on these methods in a new, separated home on the campus. Continue Reading "Building a new home on The Valley's campus is a reflection of our commitment to offering access to care" said James Peters, The Valley founder. "We have invested significantly in this campus, our team and our philosophy of treating individuals in a home like environment which has been proven to have very positive outcomes." Rockville's First Privately Operated Residential Addiction To Break Ground On New Building On Four Acres Post this The Valley is one of the few residential treatment centers that accepts most forms of insurance, including tricare for Veterans. The new residential facility has enhanced treatment options like individualize services, small group therapy sessions and opportunities for extended residential care beyond the typical 28 day inpatient. Residents will benefit from a home-like feel in a rural environment where patients are fully supported on their path to recovery. A forward approach to treating addiction, substance misuse, anxiety, depression, alcohol and prescription medication use disorder and other conditions is facilitated by qualified, experienced, and caring team of counselors, trauma therapists, nurses, clinical and medical professionals, case managers, and support staff. The program provides residents with a full day of clinical and therapeutic services with catered meals, fitness programs, yoga, acupuncture and recovery time. Therapy sessions focus on topics such as relapse prevention, life skills, self-care, trigger warnings and healthy communication. For more information about the new residence at The Valley contact Brett Goldenberg, Executive Director at The Valley Treatment Center : 301-665-7940 or [email protected] About The Valley: The Valley is a residential rehabilitation center in Rockville nestled in a valley surrounded in a beautiful natural environment. The Valley accepts most forms of insurance including Tricare, Virginia Medicaid and offers flexible payment options. If you are in need of treatment or think you might need help, call 301-355-7455 SOURCE The Valley

Tilray Led Study Shows Chronic Pain, Arthritis, Anxiety, and Insomnia as Primary Illnesses and Symptoms for Medical Cannabis Use 53.8% of Medical Cannabis Patients in Study Reported a Decrease on Prescription Opioid Use NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- Tilray Medical, a division of Tilray Brands, Inc. ("Tilray") (Nasdaq: TLRY; TSX: TLRY) and a global leader in medical cannabis, empowering the therapeutic alliance between patients and healthcare practitioners to make informed individualized health decisions, transforming healthcare, today announced a new Tilray led scientific publication, Age-related Patterns of medical Cannabis Use: A Survey of Authorized Patients in Canada. The new study was derived from the Canadian Cannabis Patient Survey (CCPS) 2021, comprised of 2,697 patients and focused primarily on older patients with a mean age of 54.3. This study presents to the medical and scientific community the consumption trends observed in patients and the self-reported impacts from medical cannabis in alleviating the patients’ primary symptoms. The Age-related Patterns of Medical Cannabis Use study finds that older patients comprise a growing subset of medical cannabis patients. The primary illnesses and symptoms for which medical cannabis was sought after by patients in this study were chronic pain (27.8%) and arthritis (14.9%) as the most common primary illnesses, pain as the most common primary symptom (66%), anxiety (9%) as the third most primary illness and second most primary symptom, and insomnia/sleep disorder as a common symptom co-morbid with chronic pain and other illnesses reported by 34.6%. Among patients taking prescription opioids, 53.8% reported a decrease in use over the past year with medical cannabis. Study participants reported that cannabis had a high degree of efficacy in alleviating their illness or symptoms, and many reported a reduction in their use of prescription opioids, alcohol, tobacco, and other substances. José Tempero, Tilray’s Medical Director, said, "Our role in this initiative exemplifies our commitment to medical research, leading us one step closer to unlocking the full therapeutic potential of medical cannabis." Tilray Medical’s mission is to continue transforming lives and fostering dignity for patients in need through access to medical cannabis, and today is a leading provider of EU-GMP certified medical cannabis products in over 20 countries with a comprehensive portfolio of THC and CBD products. Tilray has supported medical trials globally, across Europe, Canada, the United States, Australia, and Latin America, studying the efficacy of medical cannabis as a treatment for indications including pediatric epilepsy, refractory pediatric epilepsy, cancer-induced nausea and vomiting, HIV, essential tremor, breast cancer disorders, post-traumatic stress disorder, and alcohol use disorders. About Tilray Medical Tilray Medical is dedicated to transforming lives and fostering dignity for patients in need through safe and reliable access to a global portfolio of medical cannabis brands, including Tilray, Aphria, Broken Coast, Symbios and Navcora. Tilray grew from being one of the first companies to become an approved licensed producer of medical cannabis in Canada to building the first GMP-certified cannabis production facilities in Europe, first in Portugal and later in Germany. Today, Tilray Medical is one of the largest suppliers of medical cannabis to patients, physicians, hospitals, pharmacies, researchers, and governments, in 20 countries and across five continents. For more information on Tilray Medical, visit Tilray Medical Europe, Tilray Medical Canada, and Tilray Medical Australia-New Zealand. About Tilray BrandsTilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), is a leading global cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is changing people's lives for the better – one person at a time. Tilray Brands delivers on this mission by inspiring and empowering the worldwide community to live their very best life and providing access to products that meet the needs of their mind, body, and soul while invoking wellbeing. Patients and consumers trust Tilray Brands to deliver a cultivated experience and health and wellbeing through high-quality, differentiated brands and innovative products. A pioneer in cannabis research, cultivation, and distribution, Tilray’s unprecedented production platform supports over 20 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages. For more information on how we open a world of wellbeing, visit www.Tilray.com. Forward-Looking Statements Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian and U.S. securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise unless required by applicable securities laws. Contacts: Tilray Brands:Berrin Nooratanews@tilray.com InvestorsRaphael Gross203-682-8253Raphael.Gross@icrinc.com